Why the study?
CYP2C19 modulates clopidogrel dose requirements, making a simple and economic genotyping method clinically useful.
Does MGB blocker ARMS real-time PCR accurately detect CYP2C19 mutations relevant for clopidogrel dosing in a Chinese population?
Does MGB blocker ARMS real-time PCR accurately detect CYP2C19 mutations relevant for clopidogrel dosing in a Chinese population?
MGB blocker ARMS real-time PCR provides a simple and economical method for rapid detection of CYP2C19 SNPs, which can help predict clopidogrel dose requirements.
May facilitate CYP2C19 genotyping for clopidogrel; extends allele data but leaves clinical utility open.
Background: CYP2C19 is an important genetic factor modulating clopidogrel dose requirement. Objective: Therefore, a simple and economic genotyping method for predicting the clopidogrel dose of patients would be useful in clinical applications. Methods: In this study, the MGB blocker ARMS real-time PCR contained two forward primers, two MGB blockers and a common reverse primer have been used for CYP2C19*2, *3 and *17 substitutions. Results: Results showed that heterozygotes and homozygotes of CYP2C19*2, *3 and *17 could be distinguished by the MGB blocker ARMS real-time PCR successfully. In the Chinese population, patients with allele frequencies of CYP2C19*2, *3, and *17 are 18.43%, 3.03% and 0.76%, respectively. Conclusion: This study indicates that the MGB blocker ARMS real-time PCR will be a simple, economical method for the rapid detection of SNPs in CYP2C19.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: